Ophthalmology Times

We at Ophthalmology Times want you to get the most out of our content and news coverage, so we're asking you what you want to see most! Help us to ensure that we are providing the highest and most relevant content to you. Cast your vote in the poll below. If you have additional ideas or favorite pieces already on our website that you'd like to see more of share them in the comments! We appreciate your participation.

SpyGlass Pharma announced completion of enrollment in its Phase I/II, randomized, multi-center, controlled clinical trial (NCT06120842) evaluating SpyGlass’ drug delivery platform in patients with glaucoma or ocular hypertension. According to the company, its platform is designed to deliver multiple years of bimatoprost to lower intraocular pressure (IOP) and is implanted during routine cataract surgery. https://ow.ly/UuWS50UcIx3

Melt Pharmaceuticals Inc announced positive topline results from its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. According to the company, based on a Special Protocol Assessment agreement with the FDA earlier this year, the study design and these positive results support the necessary objectives required for a regulatory submission. https://ow.ly/CXig50UcIkZ

Adverum Biotechnologies, Inc. announced topline 52-week results from the LUNA Phase 2 trial, new 4-year OPTIC long-term follow-up data, and key pivotal program design elements. https://ow.ly/55ho50UcIjb

A study led by Marie Elise Wistrup Torm, MD, reveals that combining noninvasive imaging techniques can detect microscopic abnormalities in diabetic retinopathy (DR) earlier and with greater detail than traditional fundus imaging. This suggests that these advanced methods offer a more precise, timely approach to diagnosing and managing DR, a leading cause of vision loss in patients with diabetes. According to the investigators, retinal capillary imaging is particularly interesting for studying DR, which is the most common microvascular complication in diabetes, the elevated glycemic and associated glycemic instability of which lead to asymptomatic capillary wall abnormalities https://ow.ly/4tTV50UcI5S

Ocugen Inc. announced positive preliminary efficacy and safety data from the Phase 1 dose-escalation segment of the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). Read More: https://ow.ly/UTUV50UbJbR

Introducing Ophthalmology Times Focal Points! A LinkedIn newsletter that will highlight some of the biggest news from all areas of ophthalmology. Interested in what you see? Subscribe to the newsletter and go to our website for more detailed coverage!

The recent updates to cornea Preferred Practice Pattern (PPP) guidelines bring notable changes for ophthalmologists, especially concerning pediatric patients with corneal diseases. Ophthalmology Times conducted a Q&A interview with Daniel S. Choi, MD, a member of the Cornea/External Disease Panel of the PPP Committee, to discuss key revisions, including the acknowledgment of dry eye syndrome in younger patients, risks of microbial keratitis linked to orthokeratology, and recommendations for monitoring rapid progression of keratoconus in patients younger than 18 years. In this discussion, Choi highlights the importance of these evidence-based guidelines, revised every 5 years, and their role in guiding clinical practice, although they do not establish strict standards of care. Read More: https://ow.ly/1JiC50UbIPG

A newly published study reported that higher mean blood pressure (BP) levels and higher standard deviation (SD) of BP are associated with faster progression of visual field (VF) defects in patients with glaucoma. They pointed out that the association between blood pressure (BP) and glaucoma progression has been studied previously. Impaired autoregulation of the vasculature, especially in the optic nerve head, was proposed as a key risk factor for glaucomatous progression. However, it remains uncertain whether these vascular changes are a cause or a consequence of glaucoma, they commented. Read More: https://ow.ly/51th50U9uX6

The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class investigational candidate, topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease. At the same time, Aldeyra is choosing to expand their option agreement with AbbVie, granting the manufacturer more cash to bring the drug to market. Read More: https://ow.ly/FU2O50UaUgL